DNA Methylation Reveals Senolytic Treatments Do Not Reverse Epigenetic Aging

Summary Snapshot

‍Study Type: Computational meta-analysis with epigenetic predictor development

‍Sample Size: Multiple dataset cohorts, including cell lines from GSE227160, GSE197723; in vivo: 656 in GSE40279, 4,205 in FHS

‍Duration: Senolytic interventions ranged from 3 days in vitro to 6 months in vivo

‍Primary Endpoint: Response of senescence-enriched epigenetic clocks to senolytic treatment

‍

The DNA Methylation Edge


The study aimed to identify a core subset of DNA methylation CpGs associated with cellular senescence, age, and mortality to develop senescence-enriched epigenetic clocks and test their response to senolytic treatments, under the hypothesis that conserved senescence signals would improve detection of senescence and treatment effects compared to traditional clocks. It addressed inconsistencies in prior studies wherein epigenetic clocks showed unreliable associations with senescence and no reversal with senolytics, which is significant because senescence drives age-related diseases, and reliable biomarkers could accelerate clinical trials for anti-aging interventions like senolytics to extend the healthspan.

‍

Methodology

Design: Systematic meta-analysis of CpG associations with in vitro senescence, in vivo age, and mortality; elastic net regression to train senescence (binary), age (linear), and mortality (Cox) predictors; validation in independent datasets.

‍

‍Population: In vitro: Primary human cell lines (dermal fibroblasts, mesenchymal stem cells, mammary epithelial cells) from young donors. In vivo: Whole blood from healthy adults (e.g., ages 19-101 in GSE40279, mean ~70 in FHS). Senolytic cohorts: Adults with age-related conditions (e.g., mean age ~60).

‍

‍Intervention: Analysis of senolytic treatments including dasatinib + quercetin (DQ), DQ + fisetin (DQF), ABT-263 (navitoclax), Pep 14, and BI01; in vitro: Applied to senescent cells; in vivo: Oral administration over months.

‍

‍Duration: In vitro senescence induction: Days to months (e.g., serial passaging for replicative); senolytic exposure: 2-3 days in vitro, 6 months in vivo.

‍

‍Epigenetic Measurements: Infinium HumanMethylation450/EPIC BeadChips and Mammalian 320k array; Custom clocks: SenCultureAge (binary senescence predictor), SenChronoAge (age predictor), SenMortalityAge (mortality predictor), and mouse variants; trained on 9,363 (human) or 1,081 (mouse) selected CpGs.

‍

Key Findings

Results: Only 9,363 CpGs (2.4% of analyzed) showed consistent directional changes with senescence, age, and mortality; three senescence-enriched clocks (SenCultureAge, SenChronoAge, SenMortalityAge) were trained and validated, showing acceleration in replicative/oncogenic senescence and correlations with age/mortality, but none decelerated post-senolytic treatment. Rather, they trended toward acceleration (e.g., SenCultureAge accelerated after 3 months DQ). CpG changes were inconsistent across senolytics, with many moving in the same direction as senescence; mouse models and sensitivity analyses confirmed no reversal, suggesting epigenetic aging and senescence may be distinct, and clocks may not capture senolytic benefits.

‍

‍Standard Metrics: % change in biological age, direction of effect, significance. SenCultureAge: observed accelerated DNA damage senescence; no change or acceleration post-senolytic. SenChronoAge: Accelerated in replicative senescence; no significant deceleration post-senolytic. SenMortalityAge: Accelerated in replicative/oncogenic senescence; no deceleration post-senolytic. No % changes reported.

‍

‍Academic Significance: In this case, even though the research team’s findings did not align with their original hypothesis, EPBs and biological clocks helped capture these unexpected senolytic outcomes and suggest potential explanations for these results, adding to overall knowledge in the field of cellular aging and hinting at distinct cellular pathway interactions that could require further research.

‍

‍Clinical Significance: Senescent cells are apparently following a biological strategy to limit the spread of negative effects and the proliferation of damaged cells, but are also linked to increased inflammation and increased cellular aging in certain circumstances.

‍